Hemostemix Inc. (CVE:HEM – Get Free Report) was down 14.5% during trading on Tuesday . The stock traded as low as C$0.27 and last traded at C$0.27. Approximately 438,482 shares were traded during trading, a decline of 36% from the average daily volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Stock Down 14.5 %
The business’s 50 day simple moving average is C$0.11 and its 200 day simple moving average is C$0.08. The company has a market capitalization of C$23.09 million, a PE ratio of -13.25 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- 3 Tickers Leading a Meme Stock Revival
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- Upcoming IPO Stock Lockup Period, Explained
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
- What is a Death Cross in Stocks?
- Gold’s Momentum Persists: Leading ETF and 2 Stocks to Watch
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
